Repligen Corporation (RGEN)
Valuation Overview•Is Repligen Corporation Overvalued or Undervalued?
Priced at a premium to peer multiples and intrinsic cash flows, demanding strong execution to justify current levels.
Moderate quality score of 64/100, reflecting stable operating margins and manageable leverage.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Solid fundamental quality, though profitability presents a headwind.
Wall Street is highly bullish, projecting significant upside alongside robust expected earnings growth. The company currently retains all capital for reinvestment and growth rather than returning it to shareholders.
RGEN struggles with subpar profitability and pressured margins. This is supported by a highly conservative balance sheet featuring strong liquidity and pristine Altman Z safety.
The company is facing top-line contraction (-2.7% 3Y CAGR) however, earnings have severely contracted over the same period. Operating efficiency remains adequate with margins around 8.7%.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $194.3M | +16.4% | -2.7% | +15.0% | +24.3% | |
| EBITDA | $37.1M | — | -21.1% | — | — | |
| Net Income | $8.3M | +291.6% | -35.9% | — | +18.0% | |
| EPS (Diluted) | $0.15 | +287.0% | -35.7% | -5.0% | +11.9% | |
| Free Cash Flow | $23.6M | -34.1% | +34.3% | +20.9% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 51.5% | 44.8% | 49.9% | 51.7% |
| Operating Margin | 8.7% | 3.4% | 12.6% | 13.9% |
| Net Margin | 6.7% | 2.7% | 10.1% | 11.5% |
| FCF Margin | 13.7% | 15.7% | 11.8% | 10.6% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.38 | $0.48 | +26.3% | ||
| Q1'26 | $0.44 | $0.49 | +11.4% | ||
| Q4'25 | $0.42 | $0.46 | +9.5% | ||
| Q3'25 | $0.40 | $0.37 | -7.5% | ||
| Q2'25 | $0.35 | $0.39 | +11.4% | ||
| Q1'25 | $0.41 | $0.44 | +7.3% | ||
| Q4'24 | $0.34 | $0.43 | +28.2% | ||
| Q3'24 | $0.33 | $0.33 | +0.0% |
Total return is +12.3% (1Y), lagging the benchmark by -12.7%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -19.7% | -29.0% | — |
| 1Y | +12.3% | -12.7% | — |
| 3YCAGR | -4.4% | -23.6% | — |
| 5YCAGR | -7.7% | -20.2% | — |
| 10YCAGR | +19.4% | +6.6% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Repligen Corporation (RGEN) valuation, health, and returns.
Repligen Corporation is estimated to be overvalued under our discounted cash flow framework. relative multiples indicate the stock is Expensive versus peers compared to industry peers. overvalued (implying -70.8% downside from DCF intrinsic value of $38.57)
Repligen Corporation has multiple valuation anchors: DCF Intrinsic Value: $38.57 | Peer Relative Fair Value: $68.84 | Wall Street Analyst Target: $158.67 (implying +20.2% upside). A convergence of these signals offers higher conviction.
Repligen Corporation displays good financial health with a composite quality score of 64/100, supported by a Altman Z-Score of 6.0 (safe zone), Piotroski F-Score of 7/9, Return on Invested Capital (ROIC) of 2.2%.
Repligen Corporation does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Repligen Corporation's current growth trajectory is Accelerating. The company achieved +16.4% 1Y revenue growth and +287.0% 1Y EPS growth, compared to its 3Y revenue CAGR of -2.7%.
Wall Street consensus is Buy based on 24 analysts, beating EPS expectations in 67% of recent quarters with a 3-quarter streak. The consensus price target represents a +20.2% change from current levels.
Investment risks for Repligen Corporation include: -40.3% 1-year max drawdown, high beta (1.39x market volatility). Volatility risk is characterized by a beta of 1.39x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.